The global vascular closure devices market is projected to reach USD 1.3 billion by 2026 from USD 0.9 billion in 2021, at a CAGR of 7.0% during the forecast period. The growth in this market can be attributed to a large number of approvals for vascular closure devices, high prevalence of cardiovascular diseases, increasing prevalence of obesity, increasing focus of market players on large-bore vascular closure devices, growing geriatric population, favorable reimbursement scenario for interventional radiology procedures, and rising focus on effective blood loss management in patients during surgeries. Emerging markets providing growth opportunities for market players and growth in the number of hospitals & surgical centers are expected to offer strong growth opportunities for players in the market. In contrast, the need for highly skilled professionals, risks associated with vascular closure devices and stringent regulatory framework may challenge market growth to a certain extent. The vascular closure devices market is segmented based on type, access, procedure, and region.
The global vascular closure devices market is consolidated. The prominent players operating in this market include The global vascular closure devices market is consolidated. The top five companies in this market are Terumo Corporation (Japan), Abbott (US), Cardinal Health (US), Cardiva Medical, Inc. (US), Medtronic Plc (Ireland), Morris Innovative, Inc. (US), Teleflex Incorporated (US), Merit Medical Systems, Inc. (US), Vasorum Ltd. (Ireland), TZ Medical, Inc. (US), Vivasure Medical Ltd. (Ireland), Tricol Biomedical (US), Scion Biomedical (US), Advanced Vascular Dynamics (US), Marine Polymer Technologies, Inc. (US), and Rex Medical (US).
To know about the assumptions considered for the study download the pdf brochure
Terumo Corporation (Japan) is a leading player in the vascular closure devices market, with a market share of 33.4% in 2020. The company’s large share can be attributed to its broad range of vascular closure devices. The company has two distribution channels—direct to customers (healthcare professionals and/or facilities) and sales through distributors. The company has a strong presence in Japan and has established business channels primarily in Europe and the Asia Pacific.
Abbott (US) accounted for the high share of the vascular closure devices market in 2020. The company’s portfolio of vascular closure devices consists of suture-based devices, clip-based devices, and compression assist devices. The company focuses on expanding its presence in the vascular closure devices market through acquisitions.
Cardinal Health (US) held the third position in the vascular closure devices market in 2020. This can be attributed to its strong brand recognition and comprehensive suite of vascular closure devices, such as MYNX Control, MYNX Grip, EXOSEAL, and Zephyr. A majority of the company’s sales are generated from the US, and only 3% of the sales are generated outside the US. The company could focus on emerging markets for future growth.
Related Reports:
Vascular Closure Devices Market by Type (Passive Approximators, Active Approximators, External Hemostatic Devices), Access (Femoral, Radial), Procedure (Interventional Cardiology, Interventional Radiology/Vascular Surgery) - Global Forecast to 2026
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE